2-aminopyrimidine-4-carboxamide derivatives, their preparation and their
use in therapeutics
    1.
    发明授权
    2-aminopyrimidine-4-carboxamide derivatives, their preparation and their use in therapeutics 失效
    2-氨基嘧啶-4-羧酰胺衍生物,其制备及其在治疗中的应用

    公开(公告)号:US5246939A

    公开(公告)日:1993-09-21

    申请号:US903977

    申请日:1992-06-26

    CPC分类号: C07D401/12

    摘要: A compound which is a 2-aminopyrimidine carboxamide derivative represented by formula (I) ##STR1## in which X represents hydrogen, fluorine, chlorine, methyl, 1-methylethyl or methoxy, with the proviso that more than one substituent X may be present in which case each X may be the same or different,n represents 2 or 3,m represents 1, in which case p represents 1, or elsem represents 0, in which case p represents 2,q represents 0 or 1, andR.sub.1 represents a hydrogen atom;or a pharmaceutically acceptable acid addition salt thereof.A compound of formula (I) has .alpha..sub.1 -adrenergic receptor antagonist activity and is useful as a therapeutic substance.

    摘要翻译: 作为式(I)表示的2-氨基嘧啶甲酰胺衍生物的化合物,其中X表示氢,氟,氯,甲基,1-甲基乙基或甲氧基,条件是多于一个取代基X可以 在这种情况下,每个X可以相同或不同,n表示2或3,m表示1,在这种情况下p表示1,或者m表示0,在这种情况下p表示2,q表示0或1, R1表示氢原子。 或其药学上可接受的酸加成盐。 式(I)化合物具有α1-肾上腺素能受体拮抗剂活性,可用作治疗物质。

    2-((4-Piperidyl)methyl)-1,2,3,4-tetrahydroisoquinoline derivatives,
their preparation and their application in therapy
    4.
    发明授权
    2-((4-Piperidyl)methyl)-1,2,3,4-tetrahydroisoquinoline derivatives, their preparation and their application in therapy 失效
    2 - ((4-哌啶基)甲基)-1,2,3,4-四氢异喹啉衍生物,其制备及其在治疗中的应用

    公开(公告)号:US4885302A

    公开(公告)日:1989-12-05

    申请号:US228748

    申请日:1988-08-05

    摘要: A compound of formula (I) ##STR1## in which R is (a) a hydrogen atom;(b) a linear or branched (C.sub.1 -C.sub.6) alkyl group; an allyl group; a cycloalkylmethyl group in which the cycloalkyl moiety has from 3 to 6 carbon atoms; a phenylmethyl group unsubstituted or substituted with one to three substituents chosen from halogen atoms and trifluoromethyl, nitro, amino, dimethylamino, cyano, aminocarbonyl, linear or branched (C.sub.1 -C.sub.3) alkyl, linear or branched (C.sub.1 -C.sub.3) alkoxy and linear or branched (C.sub.1 -C.sub.3) alkylthio groups; a 2-phenylethyl group; a 3-phenylpropyl group; a 3-phenyl-2-propenyl group; a phenylcarbonylmethyl group; a naphthylmethyl group; a pyridylmethyl group; a furylmethyl group; or a thienylmethyl group; or(c) a linear or branched (C.sub.2 -C.sub.6) alkanoyl group; a cycloalkylcarbonyl group in which the cycloalkyl moiety has from 3 to 6 carbon atoms; a trifluoroacetyl group; a phenyl-carbonyl group unsubstituted or substituted with one to three substituents chosen from halogen atoms and trifluoromethyl, nitro, linear or branched (C.sub.1 -C.sub.3) alkyl, linear or branched (C.sub.1 -C.sub.3) alkoxy and linear or branched (C.sub.1 -C.sub.3) alkylthio groups; a 1-oxo-3-phenyl-2-propenyl group; a naphthylcarbonyl group; a pyridylcarbonyl group; a furylcarbonyl group; a thienylcarbonyl group; a (2-indolyl)-carbonyl group; or a (5-indolyl)carbonyl group; or a pharmacologically acceptable acid addition salt thereof.

    摘要翻译: 式(I)化合物其中R为(a)氢原子; (b)直链或支链(C1-C6)烷基; 烯丙基; 环烷基甲基,其中环烷基部分具有3至6个碳原子; 未取代或被一至三个选自卤素原子和三氟甲基,硝基,氨基,二甲基氨基,氰基,氨基羰基,直链或支链(C 1 -C 3)烷基,直链或支链(C 1 -C 3)烷氧基和直链或支链 支链(C1-C3)烷硫基; 2-苯基乙基; 3-苯基丙基; 3-苯基-2-丙烯基; 苯基羰基甲基; 萘基甲基; 吡啶基甲基; 呋喃甲基; 或噻吩甲基; 或(c)直链或支链(C 2 -C 6)烷酰基; 环烷基部分具有3至6个碳原子的环烷基羰基; 三氟乙酰基; 直链或支链(C1-C3)烷基,直链或支链(C1-C3)烷氧基和直链或支链的(C1-C3)烷基, 烷硫基; 1-氧代-3-苯基-2-丙烯基; 萘基羰基; 吡啶基羰基; 呋喃基羰基; 噻吩基羰基; (2-吲哚基) - 羰基; 或(5-吲哚基)羰基; 或其药理学上可接受的酸加成盐。